Quick Answer
Viking Therapeutics, Inc. reported Research And Development Expense of $344.96 million for the year ending 2025.
- Viking Therapeutics, Inc. showed an increase of +239.4% in Research And Development Expense from 2024 to 2025.
- This data is from Viking Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $50.0 thousand | Q2 2014: $21.24 million | Q3 2014: $788.6 thousand | Q1 2015: $139.0 thousand | Q2 2015: $1.10 million | Q3 2015: $2.51 million | Q1 2016: $1.88 million | Q2 2016: $2.37 million | Q3 2016: $2.10 million | Q1 2017: $3.53 million | Q2 2017: $3.72 million | Q3 2017: $3.47 million | Q1 2018: $3.04 million | Q2 2018: $5.22 million | Q3 2018: $5.69 million | Q1 2019: $4.50 million | Q2 2019: $7.33 million | Q3 2019: $5.28 million | Q1 2020: $7.99 million | Q2 2020: $7.78 million | Q3 2020: $7.12 million | Q1 2021: $11.54 million | Q2 2021: $12.80 million | Q3 2021: $10.80 million | Q1 2022: $12.56 million | Q2 2022: $13.54 million | Q3 2022: $11.96 million | Q1 2023: $11.01 million | Q2 2023: $13.92 million | Q3 2023: $18.38 million | Q1 2024: $24.10 million | Q2 2024: $23.77 million | Q3 2024: $22.79 million | Q1 2025: $41.39 million | Q2 2025: $60.15 million | Q3 2025: $89.95 million.
- Over the full 12 years of available data (2014 to 2025), Viking Therapeutics, Inc.'s Research And Development Expense has grown by 1,452.2%.
- Historical annual values: Fiscal year 2025: $344.96 million | Fiscal year 2024: $101.64 million | Fiscal year 2023: $63.81 million | Fiscal year 2022: $54.23 million | Fiscal year 2021: $44.98 million | Fiscal year 2020: $31.93 million | Fiscal year 2019: $23.56 million | Fiscal year 2018: $19.04 million | Fiscal year 2017: $13.74 million | Fiscal year 2016: $9.00 million | Fiscal year 2015: $6.97 million | Fiscal year 2014: $22.22 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: